The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
Open accessAbstract
BACKGROUND: Romiplostim, a thrombopoietin mimetic, increases platelet counts in patients with immune thrombocytopenia, with few adverse effects. METHODS: In this open-label, 52-week study, we randomly assigned 234 adult patients with immune thrombocytopenia, who had not undergone splenectomy, to receive the standard of care (77 patients) or weekly subcutaneous injections of romiplostim (157 patients). Primary end points were incidences of treatment failure and splenectomy. Secondary end points included the rate of a platelet response (a platelet count >50×10(9) per liter at any scheduled visit), safety outcomes, and the quality of life. RESULTS: The rate of a platelet response in the romiplostim group was 2.3 times that in the standard-of-care group (95% confidence interval [CI], 2.0 to 2.6; P<0.001). Patients receiving romiplostim had a significantly lower incidence of treatment failure (18 of 157 patients [11%]) than those receiving the standard of care (23 of 77 patients [30%], P<0.001) (odds ratio with romiplostim, 0.31; 95% CI, 0.15 to 0.61). Splenectomy also was performed less frequently in patients receiving romiplostim (14 of 157 patients [9%]) than in those receiving the standard of care (28 of 77 patients [36%], P<0.001) (odds ratio, 0.17; 95% CI, 0.08 to 0.35). The romiplostim group had a lower rate of bleeding events, fewer blood transfusions, and greater improvements in the quality of life than the standard-of-care group. Serious adverse events occurred in 23% of patients (35 of 154) receiving romiplostim and 37% of patients (28 of 75) receiving the standard of care. CONCLUSIONS: Patients treated with romiplostim had a higher rate of a platelet response, lower incidence of treatment failure and splenectomy, less bleeding and fewer blood transfusions, and a higher quality of life than patients treated with the standard of care. ( ClinicalTrials.gov number, NCT00415532.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Provan, D., Stasi, R., Newland, A. C., Blanchette, V. S., Bolton-Maggs, P., Bussel, J. B., Chong, B. H., Cines, D. B., Gernsheimer, T. B., Godeau, B., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225565 · Cited by 2,271
Self-citationKuter, D. J., Bussel, J. B., Lyons, R. M., Pullarkat, V., Gernsheimer, T. B., Senecal, F. M., Aledort, L. M., George, J. N., Kessler, C. M., Sanz, M. A., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60203-2 · Cited by 867
Self-citationKojouri, K., Vesely, S. K., Terrell, D. R., & George, J. N. (2004) · Blood · doi:10.1182/blood-2004-03-1168 · Cited by 653
Bussel, J. B., Provan, D., Shamsi, T., Cheng, G., Psaila, B., Kovaleva, L., Salama, A., Jenkins, J. M., Roychowdhury, D., Mayer, B., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60402-5 · Cited by 539
SPLENECTOMY AND SUBSEQUENT MORTALITY IN VETERANS OF THE 1939-45 WAR
Dennis Robinette, C., & Fraumeni, J. (1977) · The Lancet · doi:10.1016/s0140-6736(77)90132-5 · Cited by 427
Vascular complications after splenectomy for hematologic disorders
Crary, S. E., & Buchanan, G. R. (2009) · Blood · doi:10.1182/blood-2009-04-210112 · Cited by 323
Postsplenectomy Sepsis and Mortality in Adults
Schwartz, P. E. (1982) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1982.03330180039029 · Cited by 296
Nugent, D., McMillan, R., Nichol, J. L., & Slichter, S. J. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07717.x · Cited by 270
Godeau, B., Porcher, R., Fain, O., Lefrère, F., Fenaux, P., Cheze, S., Vekhoff, A., Chauveheid, M.-P., Stirnemann, J., Galicier, L., et al. (2008) · Blood · doi:10.1182/blood-2008-01-131029 · Cited by 244
George, J. N., Mathias, S. D., Go, R. S., Guo, M. D., Henry, D. H., Lyons, R. M., Redner, R. L., Rice, L., & Schipperus, M. R. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07464.x · Cited by 144
Cited by
Provan, D., Stasi, R., Newland, A. C., Blanchette, V. S., Bolton-Maggs, P., Bussel, J. B., Chong, B. H., Cines, D. B., Gernsheimer, T. B., Godeau, B., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225565 · Cited by 2,271
Self-citationAmerican Society of Hematology 2019 guidelines for immune thrombocytopenia
Neunert, C., Terrell, D. R., Arnold, D. M., Buchanan, G., Cines, D. B., Cooper, N., Cuker, A., Despotovic, J. M., George, J. N., Grace, R. F., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000966 · Cited by 1,406
Self-citationThrombopoietin receptor agonists: ten years later
Ghanima, W., Cooper, N., Rodeghiero, F., Godeau, B., & Bussel, J. B. (2019) · Haematologica · doi:10.3324/haematol.2018.212845 · Cited by 416
Self-citationNeunert, C., Noroozi, N., Norman, G., Buchanan, G. R., Goy, J., Nazi, I., Kelton, J. G., & Arnold, D. M. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12813 · Cited by 338
Kuter, D. J., Bussel, J. B., Newland, A., Baker, R. I., Lyons, R. M., Wasser, J., Viallard, J., Macik, G., Rummel, M., Nie, K., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12260 · Cited by 275
Self-citation
Metadata
- Authors
- Kuter, D. J., Rummel, M., Boccia, R., Macik, B. G., Pabinger, I., Selleslag, D., Rodeghiero, F., Chong, B. H., Wang, X., & Berger, D. P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-11-11
- Volume
- 363
- Issue
- 20
- Pages
- 1889-1899
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2153670291
- Cited by
- 427
- References
- 12
- FWCI
- 22.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia. https://app.cochat.ai/papers/10.1056/nejmoa1002625
- The paper
- Kuter, D. J., Rummel, M., Boccia, R., Macik, B. G., Pabinger, I., Selleslag, D., Rodeghiero, F., Chong, B. H., Wang, X., & Berger, D. P. (2010). Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1002625
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.